Video - Results from #10

PCF 2021 VL

BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff Details Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the adverse...
The Use of Imaging for Patient Selection for PSMA Directed Therapies – Jeremie Calais Details Alicia Morgans speaks with Jeremie Calais about the evolving landscape of theranostic and imaging modalities in prostate cancer. The discussion primarily focuses on the role of PSMA PET imaging in patient selection for PSMA-directed therapies like lutetium PSMA. Dr. Calais elaborates on the criteria used in the VISION trial and the complexities surrounding the necessity of targeted imaging for tar...